Drug-induced parkinsonism: A review of 17 years' experience in a regional pharmacovigilance center in France

Movement Disorders

Volumn 26, Issue 12, 2011, Pages 2226-2231

  Bondon Guitton, Emmanuelle ^a,b   Perez Lloret, Santiago ^a,b,c   Bagheri, Haleh ^a,b   Brefel, Christine ^a,b   Rascol, Olivier ^a,b,c   Montastruc, Jean Louis ^a,b  

^a Faculté de Médecine Centre Hospitalo universitaire   (France)

^b TOULOUSE UNIVERSITY HOSPITAL   (France)

^c INSERM   (France)

Author keywords

Adverse drug reactions; Antipsychotics; Calcium channel blockers; Dopaminergic antagonists; Drug safety; Neuroleptics; Parkinsonism; Pharmacovigilance

Indexed keywords

ACEPROMAZINE; AMIODARONE; AMISULPRIDE; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; BENSERAZIDE; BROMOCRIPTINE; CALCIUM CHANNEL BLOCKING AGENT; CARBIDOPA; CHLORPROMAZINE; CHOLINESTERASE INHIBITOR; CYAMEMAZINE; DIAZEPAM; DOPAMINE RECEPTOR BLOCKING AGENT; FLUPHENAZINE; LEVODOPA; LEVOMEPROMAZINE; LITHIUM; MUSCARINIC RECEPTOR BLOCKING AGENT; PIPOTIAZINE; PIRIBEDIL; SULPIRIDE; THIOPROPERAZINE; TIAPRIDE; TRIHEXYPHENIDYL; TRIMETAZIDINE; TROPATEPINE; UNINDEXED DRUG; VALPROIC ACID; VERALIPRIDE;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FEMALE; FRANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSONISM; PRIORITY JOURNAL; RIGIDITY;

AGE FACTORS; ANTIPSYCHOTIC AGENTS; FEMALE; FRANCE; HUMANS; LONGITUDINAL STUDIES; MALE; PARKINSON DISEASE, SECONDARY; PHARMACOVIGILANCE; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 80055085682     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23828     Document Type: Article

References (39)

1. Pollak P, Gaio J. Les effets extrapyramidaux des psychotropes. In: Rapport de Neurologie présenté au congrès de Psychiatrie et de Neurologie de Langue Française, LXXXe session, Luxembourg, 2-7 Juillet 1984. Paris: Masson; 1984: 21-37.
2. Llau ME, Nguyen L, Senard JM, et al. Drug-induced parkinsonian syndromes: a 10-year experience at a regional center of pharmaco-vigilance. Rev Neurol (Paris) 1994; 150: 757-762.
3. Montastruc JL, Llau ME, Rascol O, et al. Drug-induced parkinsonism: a review. Fundam Clin Pharmacol 1994; 8: 293-306.
4. Marti-Massó JF, Poza JJ, Lopez de Munain A. Drugs inducing or aggravating parkinsonism: a review. Therapie 1996; 51: 568-577.
5. Nguyen N, Pradel V, Micallef J, et al. Drug-induced Parkinson syndromes. Therapie 2004; 59: 105-112.
6. Spreux A, Baldin B, Chichmanian RM. Pharmacovigilance in practice. Transfus Clin Biol 1999; 6: 254-259.
7. Montastruc J, Sommet A, Lacroix I, et al. Pharmacovigilance for evaluating adverse drug reactions: value, organization, and methods. Joint Bone Spine 2006; 73: 629-632.
8. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000; 356: 1255-1259.
9. Bégaud B, Evreux JC, Jouglard J, et al. Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France. Therapie 1985; 40: 111-118.
10. de Rijk MC, Tzourio C, Breteler MM, et al. Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease. J Neurol Neurosurg Psychiatry 1997; 62: 10-15.
11. Bégaud B, Martin K, Haramburu F, et al. Rates of spontaneous reporting of adverse drug reactions in France. JAMA 2002; 288: 1588.
12. Pierfitte C, Bégaud B, Lagnaoui R, et al. Is reporting rate a good predictor of risks associated with drugs? Br J Clin Pharmacol 1999; 47: 329-331.
13. van der Heijden PGM, van Puijenbroek EP, van Buuren S, et al. On the assessment of adverse drug reactions from spontaneous reporting systems: the influence of under-reporting on odds ratios. Stat Med 2002; 21: 2027-2044.
14. Martí Massó JF, Carrera N, de la Puente E. Parkinsonism possibly caused by cinnarizine. Med Clin (Barc) 1985; 85: 614-616.
15. Chouza C, Scaramelli A, Caamaño JL, et al. Parkinsonism, tardive dyskinesia, akathisia, and depression induced by flunarizine. Lancet 1986; 1: 1303-1304.
16. Session DR, Pearlstone MM, Jewelewicz R, et al. Estrogens and Parkinson's disease. Med Hypotheses 1994; 42: 280-282.
17. Micheli FE, Pardal MM, Giannaula R, et al. Movement disorders and depression due to flunarizine and cinnarizine. Mov Disord 1989; 4: 139-146.
18. Dick RS, Barold SS. Diltiazem-induced parkinsonism. Am J Med 1989; 87: 95-96.
19. Malaterre HR, Lauribe P, Paganelli F, et al. Parkinson syndrome, a possible adverse effect of calcium inhibitors. Arch Mal Coeur Vaiss 1992; 85: 1335-1337.
20. García-Ruiz PJ, Javier Jiménez-Jiménez F, García de Yébenes J. Calcium channel blocker-induced parkinsonism: clinical features and comparisons with Parkinson's disease. Parkinsonism Relat Disord 1998; 4: 211-214.
21. Wiholm BE, Mortimer O, Boethius G, et al. Tardive dyskinesia associated with metoclopramide. Br Med J (Clin Res Ed) 1984; 288: 545-547.
22. Miller LG, Jankovic J. Metoclopramide-induced movement disorders. Clinical findings with a review of the literature. Arch Intern Med 1989; 149: 2486-2492.
23. Andrejak M, Masmoudi K, Mizon JP. Acute dyskinesia after the ingestion of antiemetics leading to emergency hospitalization. Therapie 1990; 45: 33-35.
24. AFSSAPS: Agence française de sécurité sanitaire des produits de santé. Primperan (métoclopramide). Increased risk of neurological adverse reactions following overdoses in children [in French]. Accessed June 7, 2011.
25. Gill HS, DeVane CL, Risch SC. Extrapyramidal symptoms associated with cyclic antidepressant treatment: a review of the literature and consolidating hypotheses. J Clin Psychopharmacol 1997; 17: 377-389.
26. Extrapyramidal effects of SSRI antidepressants. Prescrire Int 2001; 10: 118-119.
27. Spigset O. Adverse reactions of selective serotonin reuptake inhibitors: reports from a spontaneous reporting system. Drug Saf 1999; 20: 277-287.
28. Caley CF, Friedman JH. Does fluoxetine exacerbate Parkinson's disease? J Clin Psychiatry 1992; 53: 278-282.
29. van de Vijver DAMC, Roos RAC, Jansen PAF, et al. Start of a selective serotonin reuptake inhibitor (SSRI) and increase of antiparkinsonian drug treatment in patients on levodopa. Br J Clin Pharmacol 2002; 54: 168-170.
30. Gony M, Lapeyre-Mestre M, Montastruc J. Risk of serious extrapyramidal symptoms in patients with Parkinson's disease receiving antidepressant drugs: a pharmacoepidemiologic study comparing serotonin reuptake inhibitors and other antidepressant drugs. Clin Neuropharmacol 2003; 26: 142-145.
31. Olanow CW, Damier P, Goetz CG, et al. Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study). Clin Neuropharmacol 2004; 27: 58-62.
32. Kane J, Rifkin A, Quitkin F, et al. Extrapyramidal side effects with lithium treatment. Am J Psychiatry 1978; 135: 851-853.
33. Tyrer P, Alexander MS, Regan A, et al. An extrapyramidal syndrome after lithium therapy. Br J Psychiatry 1980; 136: 191-194.
34. Lecamwasam D, Synek B, Moyles K, et al. Chronic lithium neurotoxicity presenting as Parkinson's disease. Int Clin Psychopharmacol 1994; 9: 127-129.
35. Anglès A, Bagheri H, Saivin S, et al. Interaction between lansoprazole and bromocriptine in a patient with Parkinson's disease. Therapie 2002; 57: 408-410.
36. Cholinesterase inhibitors: tremor and exacerbation of Parkinson's disease. Prescrire Int 2007; 16: 197-198.
37. Martí Massó JF. Trimetazidine-induced parkinsonism. Neurologia 2004; 19: 392-395.
38. Martí Massó J, Martí I, Carrera N, et al. Trimetazidine induces parkinsonism, gait disorders, and tremor. Therapie 2005; 60: 419-422.
39. Sivet J, de la Gastine B, Mosquet B, et al. Trimetazidine-induced encephalopathy with choreiform disorders: a case report. Rev Med Interne 2008; 29: 512-515.